Olaparib (AZD2281, Ku-0059436)

Catalog No.S1060

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1. Phase 3.

Price Stock Quantity  
USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 370 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Olaparib (AZD2281, Ku-0059436) Chemical Structure

Olaparib (AZD2281, Ku-0059436) Chemical Structure
Molecular Weight: 434.46

Validation & Quality Control

Cited by 73 publications:

13 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Olaparib (AZD2281, Ku-0059436) is available in the following compound libraries:

PARP Inhibitors with Unique Features

  • Selective PARP Inhibitors

    AG-14361 PARP1-selective, Ki<5 nM. UPF 1069 PARP2-selective, IC50=0.3 μM.

  • Most Potent PARP Inhibitor

    MK-4827 (Niraparib) PARP1, IC50=3.8 nM; PARP2, IC50=2.1 nM.

  • PARP Inhibitor in Clinical Trial

    Iniparib (BSI-201) Phase III for solid tumors.

  • Newest PARP Inhibitor

    BMN 673 Novel PARP inhibitor with IC50 of 0.58 nM. Also a potent inhibitor of PARP-2, but does not inhibit PARG and highly sensitive to PTEN mutation. Novel PARP inhibitor with IC50

Product Information

  • Compare PARP Inhibitors
    Compare PARP Products
  • Research Area
  • Inhibition Profile
  • Olaparib (AZD2281, Ku-0059436) Mechanism

Product Description

Biological Activity

Description Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1. Phase 3.
Targets PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
Tankyrase-1 [1]
(Cell-free assay)
IC50 1 nM 5 nM 1.5 μM
In vitro Olaparib would act against BRCA1 or BRCA2 mutations. Olaparib is not sensitive to tankyrase-1 (IC50 >1 μM). Olaparib could ablate the PARP-1 activity at concentrations of 30-100 nM in SW620 cells. Olaparib is hypersensitive to BRCA1-deficient cell lines (MDA-MB-463 and HCC1937), compared with BRCA1- and BRCA2-proficient cell lines (Hs578T, MDA-MB-231, and T47D). [1] Olaparib is strongly sensitive to KB2P cells due to suppression of base excision repair by PARP inhibition, which may result in the conversion of single-strand breaks to double-strand breaks during DNA replication, thus activating BRCA2-dependent recombination pathways. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
KP3.33M2jOXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmezOEBlMYrJR|UxRTVwN{C1JEDPxE1iNITLXnUyQDV3OU[xNy=>
KP6.3NUHITXd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYqydW9yPCCmMXTJR|UxRTFyLkSyPEDPxE1iMV[xPFU2QTZzMx?=
KP7.7NHTRWndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX20JIQ>NF3Vc4dKSzVyPUW3JI5OKA>?NHnNbY0yQDV3OU[xNy=>
KB2P3.4M330cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYTQfpB6PCCmNIjaRlVKSzVyPUGyOEBOKA>?NX6yNXRDOTh3NUm2NVM>
KB2P1.21NF3GWHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYPXNHpCPCCmMlrZTWM2OD16OUC3JI5OKA>?NVLvU|A4OTh3NUm2NVM>
U373-MGMVnDfZRwfG:6aXOgRZN{[Xl?M1;0OlEh|ryPIB?=MUGyOEBpMXHJcoNz\WG|ZYOgdoFlcWG2aX;uJJNmdnOrdHn2bZR6MWmxPFk2PDdzMh?=
T98GMn;XR5l1d3SxeHnjJGF{e2G7M{\IRVEh|ryPIB?=MmS4NlQhcA>?Mlz6TY5kemWjc3XzJJJi\GmjdHnvckB{\W6|aYTpeol1gQ>?MlriNVg6PTR5MUK=
U87-MGMo\qR5l1d3SxeHnjJGF{e2G7M1XiZVEh|ryPIB?=NX7FUI91OjRiaB?=MVXJcoNz\WG|ZYOgdoFlcWG2aX;uJJNmdnOrdHn2bZR6M1rmOVE5QTV2N{Gy
UVWMmnoR5l1d3SxeHnjJGF{e2G7NUfPN3JWPTByIH7NNIK3XXczPCCqNF3uVGZKdmO{ZXHz[ZMhemGmaXH0bY9vKHOnboPpeIl3cXS7NGHHdYIyQDl3NEexNi=>
HeLaMl\hSpVv[3Srb36gRZN{[Xl?MX:1NFAhdk1?NWLTS45JPCCqMVLDZZV{\XNiYTDtc4Rme3RiZHXsZZkhcW5icnXqc4lvcW6pIH;mJJJi\GmjdHnvck1qdmS3Y3XkJGRPSSCkcnXhb5M>M1\nSlE5QTV2N{Gy
HeLaNWfCbGlQTnWwY4Tpc44hSXO|YYm=NXrXXmVmOSEQvF2gMojBNlQhcA>?NXLTe2lZTW6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhWy2yaHHz[UBienKnc4S=Mor1NVg6PTR5MUK=
T98GM13WXGZ2dmO2aX;uJGF{e2G7M2jQc|Eh|ryPIB?=MXmyOEBpMljiSY5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgV{1xcGG|ZTDhdpJme3R?MXexPFk2PDdzMh?=
L3NVPUfoEyS3m2b4TvfIlkKEG|c3H5NFv5OlU2KM7:TTC=NEXNXXo6PiCqNYPzPGI1TE2VTx?=MWDTbYdvcW[rY3HueIx6KGmwaHnibZR{KGOnbHygd5Vzfmm4YXy=NVHZWJFMOjBzMkS0OVk>
Granta-519NWr0UFl3S3m2b4TvfIlkKEG|c3H5NELSN5Y2KM7:TTC=MVm5OkBpMYLEUXNQNY\veGt{W2yrZ3j0cJkhcW6qaXLpeJMh[2WubDDzeZJ3cX[jbB?=MWqyNFEzPDR3OR?=
BTNVzq[4FLS3m2b4TvfIlkKEG|c3H5NVTRfIVoPSEQvF2gNVzlTIMyQTZiaB?=M2P5[2ROW09?MnfLV4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC|dYL2bZZidA>?M{TsVFIxOTJ2NEW5
UPN2NYj4dnN1S3m2b4TvfIlkKEG|c3H5M{DwTVUh|ryPIB?=M1XjVVk3KGh?NVH6cIFbTE2VTx?=M3fxNXNtcWeqdHz5JIlvcGmkaYTzJINmdGxic4Xyeol3[Wx?NIOyb|QzODF{NES1PS=>
HBL-2MUXDfZRwfG:6aXOgRZN{[Xl?MVq1JO69VSB?MlfCPVYhcA>?M1;XTWROW09?Ml23V4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC|dYL2bZZidA>?M4OxelIxOTJ2NEW5
JVM-2MmXDR5l1d3SxeHnjJGF{e2G7M2HxZVUh|ryPIB?=NIP6cZU6PiCqNEHyPFZFVVORMmHrV4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC|dYL2bZZidA>?M2nncFIxOTJ2NEW5
Z138NFPWemlEgXSxdH;4bYMhSXO|YYm=NWnVXW8yPSEQvF2gNI\5dW06PiCqMm\5SG1UVw>?MVXTcIlocHSueTDpcohq[mm2czDj[YxtKHO3co\peoFtMlvyNlAyOjR2NUm=
RWPENIKwdVBKdn[jc3n2[UBCe3OjeR?=MVqyOUDPxE1?MoLMOFghcA>?NFuwRYxFVVORNHr1UGtUcWewaX\pZ4FvfGy7IILl[JVk\XNiRWLHMYRzcX[nbjDj[YxtKGmwdnHzbY9vNHj0NFUzOTV5NUi2OS=>
VCaPNIXzbINKdn[jc3n2[UBCe3OjeR?=NUSwR5J5OjVizszNMn:3OFghcA>?MkLOSG1UVw>?MYnTbYdvcW[rY3HueIx6KHKnZIXj[ZMhTVKJLXTybZZmdiClZXzsJIlvfmG|aX;uMl3HNlE2PzV6NkW=
Mouse H2AX−/− ES CellsM1vaUGN6fG:2b4jpZ{BCe3OjeR?=NWH6OnpnOi53IN88US=>Mn;RNlAhcA>?NXTxU2l4W2mpbnnmbYNidnSueTDpcohq[mm2czDj[YxtKHO3co\peoFtMlK3NlM{PTV2OEm=
Mouse ATM−/− ES CellsMW\DfZRwfG:6aXOgRZN{[Xl?NW\H[phqOi53IN88US=>NHPRO5AzOCCqMXXTbYdvcW[rY3HueIx6KGmwaHnibZR{KGOnbHygd5Vzfmm4YXy=NX3WUnVyOjN|NUW0PFk>
H1650NVro[5Q2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEnnOWEzOCEQvF2=NHrGR|cyPDRiaB?=Ml\kTWM2OD1zNT60O{DPxE1?MnLyNlMzOzl6MEm=
H1650PTEN+NVvWSFFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWeyNEDPxE1?Mln6NVQ1KGh?MmX0TWM2OD13MD64N{DPxE1?NV63VG1MOjN{M{m4NFk>
PC-9M33OfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn3zNlAh|ryPNFPsT4IyPDRiaB?=M2TKcmlEPTB;NT64PEDPxE1?MUSyN|I{QThyOR?=
PC-9PTEN−NX;Kd3VDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NY[4TlZpOjBizszNM2rGSlE1PCCqNUXyWIlFUUN3ME22MlUzKM7:TR?=MYeyN|I{QThyOR?=
MDA-MB-231NWLGUFU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWq2SGt{PSCmYYm=NYPhXIgzUUN3ME22Mlkh|ryPMmL5NlM4PjB2OU[=
MDA-MB-468NFzxXHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXj0TlBoPSCmYYm=NWrSfGtqUUN3ME21MlAh|ryPMnq3NlM4PjB2OU[=
BT20MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4X1TlUh\GG7Ml;wTWM2OD15Lkeg{txONEnGTXgzOzd4MES5Oi=>
HCC1143M4HjVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4nPfFUh\GG7NXLXW29SUUN3ME2xNU4yKM7:TR?=MUiyN|c3ODR7Nh?=
HCC1937MonQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYHkOYpGPSCmYYm=NYPXVYh5UUN3ME2xNk43KM7:TR?=M1PvW|I{PzZyNEm2
Hs578tNHHxWWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYLBb25[PSCmYYm=MVHJR|UxRTVwNjFOwG0>M1rnPFI{PzZyNEm2
Hs578t(si)Mk[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoTJOUBl[Xl?NEXoZ4tKSzVyPUeuOUDPxE1?MU[yN|c3ODR7Nh?=
BT474NFz2Z3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWK1JIRigQ>?M2r2XWlEPTB;MUmuPEDPxE1?M{XBO|I{PzZyNEm2
JIMT1NFfGRohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4rYcFUh\GG7M1Xvb2lEPTB;Nz63JO69VQ>?NFK2TYwzOzd4MES5Oi=>
SKBR3MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{HkSVUh\GG7NHj3VVlKSzVyPUGxMlEh|ryPM2fsNlI{PzZyNEm2
SUM159M4qzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUC1JIRigQ>?M1ezemlEPTB;ND6yJO69VQ>?MUmyN|c3ODR7Nh?=
CAMA1M2jGV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmjCOUBl[Xl?NVjvUZROUUN3ME2xOU45KM7:TR?=NWTzU40{OjN5NkC0PVY>
MCF7NFvnW5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV21JIRigQ>?Mor4TWM2OD13Lkig{txONEPK[|EzOzd4MES5Oi=>
T47DM4\0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2Xie|Uh\GG7MUjJR|UxRTlwNjFOwG0>MYCyN|c3ODR7Nh?=
HCT116M{\1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mmq3NVAxKM7:TR?=M1vEfVQ5KGh?M2PLTmROW09?NH;5bolKSzVyPUKuOUDPxE1iNGjW[2IzPDV5N{m0NS=>
SW1116M4nMZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M33uRlExOCEQvF2=MmfPOFghcA>?NYL2d203TE2VTx?=NF7R[2ZKSzVyPUGwNEDPxE1?NHzMNoIzPDV5N{m0NS=>
HT29MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWDFTGJjOTByIN88US=>NIHwOIQ1QCCqMYXEUXNQMkLsTWM2OD1zND63JO69VQ>?M4HhWVI1PTd5OUSx
LoVoNGrEXplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWWxNFAh|ryPMWm0PEBpNWD2c|lYTE2VTx?=NULMeHhvUUN3ME2xN{41KM7:TR?=M4W0TFI1PTd5OUSx
HCT-15NETpcVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV35VFJkOTByIN88US=>NIroWZc1QCCqNWnJdVRiTE2VTx?=MmLpTWM2OD1zMDFOwG0>M3XOW|I1PTd5OUSx
SW48MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1yySlExOCEQvF2=MorxOFghcA>?NX3KSGVQTE2VTx?=Mn7GTWM2OD17LkWg{txOM2jocVI1PTd5OUSx
C-1NXqzT4tKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXqzVFdnOTByIN88US=>NITyfWs1QCCqNHracZpFVVORNHHpXGRKSzVyPUeuOkDPxE1?M3rIPVI1PTd5OUSx
RKOM1HOXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3j6clExOCEQvF2=MlW4OFghcA>?NYnC[pltTE2VTx?=MmTtTWM2OD13Lkmg{txONYLWVVlNOjR3N{e5OFE>
HCT116M2\DXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYexNFAh|ryPM3rTSlQ5KGh?M3LV[mROW09?MnqzVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>?NY\OXoZvOjR3N{e5OFE>
SW1116NFv5bmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnHYNVAxKM7:TR?=NVXxRpg2PDhiaB?=M1:5XGROW09?MXrQc5RmdnSrYYTld{BUVi1|ODDjfZRwfG:6aXPpeJkhMUSyOFU4Pzl2MR?=
HT29NVjTem41T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVPEOYY4OTByIN88US=>MWe0PEBpMorrSG1UVw>?NWjOXHZmWG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?=M4LN[FI1PTd5OUSx
LoVoNH60U4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4qyOVExOCEQvF2=MnX6OFghcA>?MnTmSG1UVw>?Ml3DVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>?NInvO|YzPDV5N{m0NS=>
SW48MmCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIL2NY4yODBizszNNWXtNopnPDhiaB?=NGDWWFlFVVORNEPybIJRd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHliMlPsNlQ2Pzd7NEG=
C-1NW\SZlJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3\BWVExOCEQvF2=NV;ZXFFoPDhiaB?=NGP6SlVFVVORMkHLVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>?NHrLTlQzPDV5N{m0NS=>
RKONUDDUVZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXSwc2htOTByIN88US=>MnTWOFghcA>?MWPEUXNQM4DBRnBwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB?MXqyOFU4Pzl2MR?=
HCT116NVjOVIlmTnWwY4Tpc44hSXO|YYm=M1OyNFExKG6PMnzuNVIhcA>?Mne5SG1UVw>?NYmzVY42UW6lcnXhd4V{KESQQTDkc5VjdGVvc4TyZY5lKGK{ZXHrd{BqdmS3Y3XkJIJ6KFOQLUO4NVv2WI1sOjR3N{e5OFE>
HT29NV;GSmZuTnWwY4Tpc44hSXO|YYm=Mmi1NVAhdk1?NXfUeYhHOTJiaB?=MVfEUXNQMkm4TY5kemWjc3XzJGRPSSCmb4XicIUue3S{YX7kJIJz\WGtczDpcoR2[2WmIHL5JHNPNTN6NVzFdGF3OjR3N{e5OFE>
TE-6MmG4SpVv[3Srb36gRZN{[Xl?NXfXVXhEPSEQvF2gMn24NVIhcA>?Mlf2SG1UVw>?NIrYXVNKdmS3Y3XzJGczN01iYYLy[ZN1NHWzcFEzPDJzOUG2OC=>
TE-6NU\TTIdGTnWwY4Tpc44hSXO|YYm=MmrNOUDPxE1iMXKyOEBpNIixcYRFVVORNVrVUIFtUW6lcnXhd4V{KGmwIHTveYJt\SC|dILhcoQh[nKnYXvzJEhFW0K|KR?=MVuyOFIyQTF4NB?=
Hep3BNVXrbGhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXq3WXJ7PDBizszNJC=>NXvVd4NwPzJiaB?=NYm4T5V[TE2VTx?=MX7TfY5memerc4TpZ4FtdHliaX7obYJqfHNiY3XscEBoem:5dHige4l1cCCGSF3FVS=>MmDZNlUxPzJ5NUK=
Huh7NX;MRZA4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYPic4FnPDBizszNJC=>MYi3NkBpM{HLW2ROW09?NUTQPWFnW3mwZYLnbZN1cWOjbHz5JIlvcGmkaYTzJINmdGxiZ4Lve5RpKHerdHigSGhOTVF?M17hTVI2ODd{N{Wy
Hep3BNGjmbm1HfW6ldHnvckBCe3OjeR?=M4LhVlQxKM7:TTC=NFzJfnAzPCCqMoTiSG1UVw>?NF\NR3FKdmS3Y3XzJHJQWyCycn;keYN1cW:wIIfpeIghTEiPRWG=NWf0OoFqOjVyN{K3OVI>
Huh7MlOzSpVv[3Srb36gRZN{[Xl?MUO0NEDPxE1iNYj4bnN2OjRiaB?=M{f6emROW09?M{\m[mlv\HWlZYOgVm9UKHC{b3T1Z5Rqd25id3n0bEBFUE2HUR?=NID5NnYzPTB5Mke1Ni=>
Hep3BM4[1R2Z2dmO2aX;uJGF{e2G7NHjSOm41OCEQvF2gMVGyOEBpMo\VSG1UVw>?NWn4SoVUUW6mdXPld{Bk\WyuIHH1eI9xcGGpeTD3bZRpKESKTVXRMkLNNlUxPzJ5NUK=
Huh7NF\sNGVHfW6ldHnvckBCe3OjeR?=NVzHfVlOPDBizszNJC=>NX7Ze|FrOjRiaB?=M3XVRmROW09?MormTY5lfWOnczDj[YxtKGG3dH;wbIFogSC5aYToJGRJVUWTMlHtNlUxPzJ5NUK=
SGC-7901M3jnXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmHpN|DDqM7:TR?=NGLUNZQ1QCCqNWfiTm5{TE2VTx?=M1LjWWJtd2OtIH;4ZYxqeGyjdHnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=>MXyyOVc3PzB5Nh?=
COLO-800NUC2W5YzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4K2dGlEPTB;MD60OFE3PCEQvF2=NIPtWHZUSU6JRWK=
EoL-1-MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXPxSJhmUUN3ME2wMlU3PDR4IN88US=>M4fuRnNCVkeHUh?=
NCI-H209NGOzOI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MorqTWM2OD1yLkmxOVU3KM7:TR?=NYXoPIlzW0GQR1XS
ES1MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIHkPGFKSzVyPUGuNVE1ODhizszNMYXTRW5ITVJ?
NKM-1MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXrZUlV3UUN3ME2xMlI2OzR5IN88US=>NF\GPG9USU6JRWK=
NTERA-S-cl-D1NVruTmJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF;vWnVKSzVyPUGuN|M{PDFizszNMoPQV2FPT0WU
MHH-ES-1NUf2ZXJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX\mfmlVUUN3ME2xMlYzODZ5IN88US=>MYnTRW5ITVJ?
ES8MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3\ZO2lEPTB;MT63NlQyPCEQvF2=NGHk[ZVUSU6JRWK=
NCI-H720MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRTJwMkC2PVkh|ryPMmW2V2FPT0WU
EW-3M1fKU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3i3WGlEPTB;Mj6yO|U{PCEQvF2=MoXkV2FPT0WU
D-566MGNH;ZWGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGrDfVhKSzVyPUKuOFQ2PjhizszNMYnTRW5ITVJ?
697MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MojqTWM2OD1{Lki0NVc{KM7:TR?=MkTnV2FPT0WU
ES5MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWfJR|UxRTJwOEixPFkh|ryPNH3USHJUSU6JRWK=
COLO-684M4jjSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX;idIJUUUN3ME2zMlUyPjl4IN88US=>NHjle|hUSU6JRWK=
ML-2MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWDyTm55UUN3ME2zMlYxODV6IN88US=>Mn32V2FPT0WU
MC-IXCNYPCXGUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFvTS4NKSzVyPUOuOlM{QTNizszNM4DTT3NCVkeHUh?=
DBNFn0ToNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVX2[ZFnUUN3ME2zMlY2PDR6IN88US=>NVTvV5IxW0GQR1XS
HCC2218MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWHJR|UxRTNwN{OxNFMh|ryPMVnTRW5ITVJ?
NCI-H510ANHPqbJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUnhTXVKUUN3ME2zMlgzPzJ2IN88US=>NV3BeIVmW0GQR1XS
NCI-H526NYW5TGxoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWrJR|UxRTNwOE[5OVgh|ryPNFrib|hUSU6JRWK=
MV-4-11MnjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYr6XZZGUUN3ME20MlE{OzN2IN88US=>M{TNWnNCVkeHUh?=
PA-1NYnnU49WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MULJR|UxRTRwMkWyPUDPxE1?MV7TRW5ITVJ?
EW-22NV7OWpRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M33vZ2lEPTB;ND6zOVg3KM7:TR?=MnTjV2FPT0WU
KASUMI-1M3nMSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmPTTWM2OD12LkSwNVA6KM7:TR?=M3nBe3NCVkeHUh?=
LU-139NUjTd|l2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUj1fXp2UUN3ME20Mlc2QDJ7IN88US=>MYXTRW5ITVJ?
SBC-1Mmj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2XmUGlEPTB;ND64NFkxQCEQvF2=M1:0ZnNCVkeHUh?=
H4MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1\LTGlEPTB;ND64PVQ1OyEQvF2=NWX0ZoI6W0GQR1XS
EW-11MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmW2TWM2OD13LkC4NFczKM7:TR?=MnzGV2FPT0WU
NBsusSRNGHXUHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHHTRVVKSzVyPUWuNVIxPTVizszNNH3z[W9USU6JRWK=
RPMI-8226MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGe0V2ZKSzVyPUWuNVUzPDRizszNMoC5V2FPT0WU
DELMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoHHTWM2OD13LkKwNFA3KM7:TR?=Mn7LV2FPT0WU
ES4NH3FfWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIXqTHBKSzVyPUWuOVE{QDlizszNNYjXTYlbW0GQR1XS
GCTMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFOxU|hKSzVyPUWuOVY5PTZizszNNH;1VJBUSU6JRWK=
NCI-H1048NYDzbndRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkPFTWM2OD13Lkm3Nlc{KM7:TR?=M{DOUHNCVkeHUh?=
NCI-SNU-1MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml3CTWM2OD14LkCyNkDPxE1?M37jcnNCVkeHUh?=
ES7MofXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4DJTGlEPTB;Nj6wN|U4PyEQvF2=MWXTRW5ITVJ?
SW982M{i1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoHsTWM2OD14LkC5NVM4KM7:TR?=MXPTRW5ITVJ?
L-363MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXzFb21wUUN3ME22MlM{QTd2IN88US=>M1vJPHNCVkeHUh?=
HT-1080MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGTufYNKSzVyPU[uOFk3QDNizszNMkPaV2FPT0WU
HAL-01MkDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX;JR|UxRTZwNUGwPUDPxE1?MlfaV2FPT0WU
NB14MlzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX\JR|UxRTZwNkSwN|kh|ryPMk\LV2FPT0WU
EW-13NWTSTHRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV;FUYFJUUN3ME22Mlc4PDJ2IN88US=>NW\tc|RkW0GQR1XS
NYNVu1V5JyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX7JR|UxRTZwOUS2NFUh|ryPNGXwTIdUSU6JRWK=
NCI-SNU-5MkP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn\RTWM2OD15LkGwOFM{KM7:TR?=NUPi[lliW0GQR1XS
MS-1NEPFfINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVvJR|UxRTdwMUe0PVQh|ryPMnr0V2FPT0WU
EW-16NEnEVWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEO3NGJKSzVyPUeuN|E5PjFizszNNXG2XZR1W0GQR1XS
LU-65MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXiwXJNSUUN3ME23MlQ5PDF5IN88US=>MY\TRW5ITVJ?
HGC-27MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYTJR|UxRTdwN{KxO|Mh|ryPMoTtV2FPT0WU
CTB-1NVGzPI9pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{j3c2lEPTB;Nz63OlE4PSEQvF2=NECzN29USU6JRWK=
5637NULZR5lYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIH5cWlKSzVyPUeuPVI5PiEQvF2=Mkm1V2FPT0WU
U251MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYq0VGRYUUN3ME23Mlk1ODF4IN88US=>NW\v[m9uW0GQR1XS
HOSM{nSbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnzKTWM2OD16LkKzNFA4KM7:TR?=MnzSV2FPT0WU
DOHH-2Mm\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYjlSY1VUUN3ME24MlI{PThizszNM1P5[XNCVkeHUh?=
EW-1M3GwVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFO5UFRKSzVyPUiuN|AxQDhizszNMWPTRW5ITVJ?
BV-173NUDJc3FHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX;JR|UxRThwNUW1OEDPxE1?MVvTRW5ITVJ?
8-MG-BANWrSUWZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWn2VWFrUUN3ME24MlY5QTh6IN88US=>NGHMc29USU6JRWK=
NB69NXPu[oNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoryTWM2OD16LkewPVIyKM7:TR?=MUPTRW5ITVJ?
NCI-H69MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYDJR|UxRTlwOUC5OlEh|ryPNVvXZXFCW0GQR1XS
RS4-11MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYXJR|UxRTFzLkKyNFgh|ryPMlziV2FPT0WU
ONS-76MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIHReG5KSzVyPUGxMlI6PDdizszNMnLBV2FPT0WU
SF539NVPNc29rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnXUTWM2OD1zMT60PFg6KM7:TR?=M1nUbXNCVkeHUh?=
HuO-3N1MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYHFb|Z3UUN3ME2xNU42Pzl4IN88US=>NF\MbFJUSU6JRWK=
NCI-H1651NELxbpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVLJR|UxRTF{LkOxNVUh|ryPNIXQe2RUSU6JRWK=
KARPAS-45NGjrNZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFu2VFVKSzVyPUGyMlM4PiEQvF2=M4G1VnNCVkeHUh?=
SK-NEP-1NHvENnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFq2b41KSzVyPUGyMlQ3ODlizszNNGTQWW9USU6JRWK=
LAMA-84NF\IN4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M33kcGlEPTB;MUOuNVA6PSEQvF2=NYXvZpZwW0GQR1XS
NCI-H1155MljwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NULqb3kxUUN3ME2xN{4zQDV4IN88US=>M2HubXNCVkeHUh?=
CTV-1MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoOzTWM2OD1zMz60OFUh|ryPNX\uRVdRW0GQR1XS
QIMR-WILMmfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3PPfWlEPTB;MUOuO|gyPCEQvF2=MXLTRW5ITVJ?
H9MlLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH:xO41KSzVyPUGzMlg1PzVizszNNVS5OIp6W0GQR1XS
SK-MEL-1M1rh[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmrvTWM2OD1zMz65N|Q4KM7:TR?=MYLTRW5ITVJ?
HD-MY-ZMXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmnVTWM2OD1zND6wOlM4KM7:TR?=MVTTRW5ITVJ?
TI-73NF[yTopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHy0[HlKSzVyPUG0MlI{PTZizszNMWPTRW5ITVJ?
JVM-3NH\WO2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUPJR|UxRTF3LkW3NVYh|ryPMljOV2FPT0WU
D-247MGMVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHLJOnpKSzVyPUG1MlU6OyEQvF2=NEXHUohUSU6JRWK=
VA-ES-BJM4XWbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVPWfXB7UUN3ME2xOU43ODl5IN88US=>NWTKN3oyW0GQR1XS
NOS-1NUDENG92T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3roWWlEPTB;MUWuOlUzOiEQvF2=NUnNU|lHW0GQR1XS
MOLT-4NETQ[VlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmfLTWM2OD1zNj63OVIh|ryPNXzpS|Y{W0GQR1XS
Mo-TNFLCS2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH;mXGVKSzVyPUG3MlA5PDlizszNM37OSXNCVkeHUh?=
NCI-H1770MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MljOTWM2OD1zNz6xOVQ{KM7:TR?=MXvTRW5ITVJ?
COLO-320-HSRNUn3PXhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUHJR|UxRTF5LkG4Nlch|ryPMnnxV2FPT0WU
TE-12MnXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M334[GlEPTB;MUeuO|A2PCEQvF2=MYrTRW5ITVJ?
NCI-H82M1voXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYPQOFJCUUN3ME2xO{45PzJ6IN88US=>NFzjOmRUSU6JRWK=
NEC8NHLJNnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MY\JR|UxRTF6LkGzNVYh|ryPM1PUb3NCVkeHUh?=
HSC-3MnnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX;JR|UxRTF6Lke0NVQh|ryPMWnTRW5ITVJ?
NCI-H1092NF;O[3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmLhTWM2OD1zOD63OVk2KM7:TR?=MXPTRW5ITVJ?
NCI-H292M3fRPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M37admlEPTB;MUmuNFQ5QSEQvF2=NV;ufWg5W0GQR1XS
L-428MnLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkjjTWM2OD1zOT61OVkh|ryPMnjTV2FPT0WU
LU-134-ANVz4eYhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1\4cWlEPTB;MUmuOVczKM7:TR?=NVXHeFE2W0GQR1XS
GI-ME-NNVLFTHJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4G1VGlEPTB;MUmuOVc1PyEQvF2=MXnTRW5ITVJ?
ALL-PONHfuTWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUfsZZN7UUN3ME2xPU42QTd{IN88US=>NFLjWG1USU6JRWK=
D-283MEDMk\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlLjTWM2OD1zOT65NVUh|ryPMn\VV2FPT0WU
D-423MGM2\QUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NW\Tb3I{UUN3ME2xPU46QTZ5IN88US=>MV7TRW5ITVJ?
CAKI-1MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn3yTWM2OD1{MD6yNlE6KM7:TR?=MlzXV2FPT0WU
ETK-1M3LwTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXnnVohiUUN3ME2yNE4zPjF3IN88US=>MYfTRW5ITVJ?
G-402MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MULJR|UxRTJyLkWzN|Qh|ryPM{\JOXNCVkeHUh?=
HL-60NWez[VVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2jnNGlEPTB;MkGuNVYyOyEQvF2=M2K1U3NCVkeHUh?=
A2058MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWmxOGhUUUN3ME2yNU41PDd5IN88US=>NF\rV2ZUSU6JRWK=
CHP-212NHHvdmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoXGTWM2OD1{MT65NFUyKM7:TR?=NH3FXYlUSU6JRWK=
KY821M{\4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYHJR|UxRTJzLkm3OUDPxE1?MYrTRW5ITVJ?
TYK-nuNXrreYJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGfXeFhKSzVyPUKyMlA3PTFizszNMl3lV2FPT0WU
JVM-2MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWnJR|UxRTJ{LkK5PFMh|ryPNGXNdG1USU6JRWK=
KU812NH7VeldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXzZOZN1UUN3ME2yNk44OzF{IN88US=>MYnTRW5ITVJ?
MKN28M{f1UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlHLTWM2OD1{Mj65NFE2KM7:TR?=M3fERXNCVkeHUh?=
ECC10NV\QSFFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4[0OGlEPTB;MkOuO|QyKM7:TR?=NWDWUVc1W0GQR1XS
BHT-101MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVnHXpFoUUN3ME2yOE4xODB6IN88US=>NXPKSYdXW0GQR1XS
DU-4475NU\1fXdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFi5dppKSzVyPUK0MlM{OzdizszNMX\TRW5ITVJ?
769-PMl;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NInNS2FKSzVyPUK0Mlg1PjZizszNM1Hsd3NCVkeHUh?=
HEC-1MmHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NILKfo5KSzVyPUK1MlQ1PSEQvF2=MXfTRW5ITVJ?
MOLT-13NEPVU4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmWzTWM2OD1{NT61N|MyKM7:TR?=MmP3V2FPT0WU
8505CNHvne21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkfjTWM2OD1{Nj60PVc4KM7:TR?=MnjFV2FPT0WU
GB-1NH3IO4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3HXbWlEPTB;Mk[uO|E4PiEQvF2=NHflU|VUSU6JRWK=
SF126Mo\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIfycXRKSzVyPUK2Mlc3PDhizszNNY\qRoFiW0GQR1XS
A4-FukMUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHjrfHNKSzVyPUK3MlEzPzFizszNNXG4cm95W0GQR1XS
OVCAR-8NIPrS2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVfJR|UxRTJ5LkG1N|kh|ryPMV3TRW5ITVJ?
NCI-H1304NFTXVpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml\kTWM2OD1{Nz61OEDPxE1?MYnTRW5ITVJ?
GR-STNWnlU5lMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MULJR|UxRTJ6LkC0O{DPxE1?MkGyV2FPT0WU
G-401MlniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoXUTWM2OD1{OD61NFk3KM7:TR?=NV7QOVlyW0GQR1XS
LXF-289NUXwSXVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{HwdGlEPTB;MkiuOVY2OSEQvF2=NYLo[5dvW0GQR1XS
DBTRG-05MGMmXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{i4O2lEPTB;MkiuPVIxPCEQvF2=NXLPfG1OW0GQR1XS
YKG-1MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1K5cmlEPTB;MkmuPFY5KM7:TR?=MYHTRW5ITVJ?
GAMGNIXFelhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4\IdGlEPTB;MkmuPVk{KM7:TR?=MnXTV2FPT0WU
HCT-116Mnj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUXJR|UxRTNyLkC1OFgh|ryPNH7yVnJUSU6JRWK=
S-117MlzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3\s[WlEPTB;M{GuNlI2PyEQvF2=NVrBR4ozW0GQR1XS
NCI-H1693M{PjV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHHDfmdKSzVyPUOzMlY2PDJizszNMUPTRW5ITVJ?
A427MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoLnTWM2OD1|Mz65PVc3KM7:TR?=NXr4SVc{W0GQR1XS
HT-29NFX1R21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXXJR|UxRTN2Lk[wN|Ih|ryPMnzXV2FPT0WU
P12-ICHIKAWAMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFHFUIRKSzVyPUO0Mlc1QTFizszNNHHhNJlUSU6JRWK=
CAL-51MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYLJR|UxRTN3LkC3NFkh|ryPNVrGZ3VJW0GQR1XS
Ramos-2G6-4C10MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVfJR|UxRTN3LkK0NlUh|ryPM4T4XnNCVkeHUh?=
SCHNU\xXmRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MniwTWM2OD1|Nj60NVc1KM7:TR?=NVLVVJFpW0GQR1XS
SK-MEL-24MlzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHLNZXZKSzVyPUO2MlkxPDRizszNNFPLZ|BUSU6JRWK=
SW1573NImwbHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXnJR|UxRTN6LkeyNVYh|ryPMWHTRW5ITVJ?
BALL-1Ml7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1m1[mlEPTB;M{muNlEzQSEQvF2=NH\nTFRUSU6JRWK=
BE-13MonYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NY\GNo4xUUN3ME2zPU4{OjlizszNMXjTRW5ITVJ?
GI-1NHPUVWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUfJR|UxRTN7Lki2OFch|ryPNW\DPGlCW0GQR1XS
GOTOMorNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1LTemlEPTB;M{muPVE{QSEQvF2=NF\vcJVUSU6JRWK=
A673NYrYVY5xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWrpSpN3UUN3ME20NU4xOzR|IN88US=>MnHRV2FPT0WU
KG-1MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoXLTWM2OD12Mz6zPVQh|ryPMXTTRW5ITVJ?
GP5dMV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFvlbXVKSzVyPUS0MlA3PjZizszNMmLqV2FPT0WU
MFM-223NEfIfZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH\pV|FKSzVyPUS0MlEzOjhizszNNYi3NoRTW0GQR1XS
OAW-42MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MknuTWM2OD12ND6yOlQ{KM7:TR?=MWrTRW5ITVJ?
C8166MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYXJR|UxRTR3LkC4NlIh|ryPM2nKPHNCVkeHUh?=
LU-99AM3nBfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVfWN|ZQUUN3ME20Ok4yOzJ{IN88US=>M1Tx[XNCVkeHUh?=
NCI-H23MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4S5WmlEPTB;NE[uNVc5PSEQvF2=MYnTRW5ITVJ?
HO-1-N-1M3P0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUnxeHJCUUN3ME20O{4xQTl6IN88US=>NF\nWVRUSU6JRWK=
A3-KAWNHXhV2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYLJR|UxRTR5LkGwNFch|ryPMnf3V2FPT0WU
CGTH-W-1MoLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml:1TWM2OD12Nz61NFY6KM7:TR?=M3jYSXNCVkeHUh?=
DJM-1NGfNbWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYHJR|UxRTR5LkW0NVMh|ryPMnnxV2FPT0WU
A101DNF[ySGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3f1WGlEPTB;NEeuOlM2PyEQvF2=MVPTRW5ITVJ?
BB30-HNCNX72bHI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVvncFRnUUN3ME20PE4{ODd{IN88US=>NF:wenpUSU6JRWK=
T98GNWfkdmlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{nDUGlEPTB;NEiuOFY{OyEQvF2=NYP0WJIxW0GQR1XS
NCI-H1573M3XFfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2fQdWlEPTB;NEmuOFQ3OiEQvF2=M{LVR3NCVkeHUh?=
MEG-01MkDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MonCTWM2OD12OT63OFEyKM7:TR?=MmHZV2FPT0WU
WM-115M332Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoLuTWM2OD12OT65NlIzKM7:TR?=NH;xXoFUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Combining with temozolomide, Olaparib (10 mg/kg, p.o.) significantly suppresses tumor growth in SW620 xenografts. [1] Olaparib shows great response to Brca1-/-;p53-/- mammary tumors (50 mg/kg i.p. per day), while no responses to HR-deficient Ecad-/-;p53-/- mammary tumors. Olaparib even does not show dose-limiting toxicity in tumor-bearing mice. [3] Olaparib has been used to treat with BRCA mutated tumors, such as ovarian, breast and prostate cancers. Moreover, Olaparib shows selectively inhibition to ATM (Ataxia Telangiectasia Mutated)-deficient tumor cells, which indicates to be a potential agent for treating ATM mutant lymphoid tumors. [4]
Features A potent PARP inhibitor (currently in late stage clinical trials).

Protocol(Only for Reference)

Kinase Assay:

[1]

FlashPlate assay (96-well screening assay) To columns 1 through 10, 1 μL of Olaparib (in DMSO) is added, and 1 μL DMSO only is added to the positive (POS) and negative (NEG) control wells (columns 11 and 12, respectively) of a pretreated FlashPlate. PARP-1 is diluted 1:40 in buffer (buffer B: 10% glycerol (v/v), 25 mM HEPES, 12.5 mM MgCl2,50 mM KCl, 1 mM DTT, 0.01% NP-40 (v/v), pH 7.6) and 40 μL added to all 96 wells (final PARP-1 concentration in the assay is ~1 ng/μL). The plate is sealed and shaken at RT for 15 min. Following this, 10 μL of positive reaction mix (0.2 ng/μL of double-stranded oligonucleotide [M3/M4] DNA per well, 5 μM of NAD+ final assay concentration, and 0.075 μCi 3H-NAD+ per well) is added to the appropriate wells (columns 1-11). The negative reaction mix, lacking the DNA oligonucleotide, is added to column 12 (with the mean negative control value used as the background). The plate is resealed and shaken for a further 60 min at RT to allow the reaction to continue. Then, 50 μL of ice-cold acetic acid (30%) is added to each well to stop the reaction, and the plate is sealed and shaken for a further 60 min at RT. Tritiated signal bound to the FlashPlate is then determined in counts per minute (CPM) using the TopCount plate reader.
In vitro isolated enzyme assay PARP-2 activity inhibition uses a variation of the PARP-1 assay in which PARP-2 protein (recombinant) is bound down by a PARP-2 specific antibody in a 96-well white-walled plate. PARP-2 activity is measured following 3H-NAD+ DNA additions. After washing, scintillant is added to measure 3H-incorporated ribosylations.

Cell Assay:

[1]

Cell lines Breast cancer cell lines including SW620 colon, A2780 ovarian, HCC1937, Hs578T, MDA-MB-231, MDA-MB-436, and T47D
Concentrations 1-300 nM
Incubation Time 7-14 days
Method

The cytotoxicity of Olaparib is measured by clonogenic assay. Olaparib is dissolved in DMSO and diluted by culture media before use. The cells are seeded in six well plates and left to attach overnight. Then Olaparib is added at various concentrations and the cells are incubated for 7-14 days. After that the surviving colonies are counted for calculating the IC50.

Animal Study:

[3]

Animal Models Brca1-/-;p53-/- mammary tumors are generated in K14cre;Brca1F/F;p53F/F mice.
Formulation 50 mg/mL stocks in DMSO with 10% 2-hydroxyl-propyl-β-cyclodextrine/PBS
Dosages 50 mg/kg
Administration Administered via i.p. injection at 10 μL/g of body weight

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Menear KA, et al. J Med Chem, 2008, 51(20), 6581-6591.

[2] Evers B, et al, Clin Cancer Res, 2008, 14(12), 3916-3925.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02546661 Not yet recruiting Muscle Invasive Bladder Cancer AstraZeneca August 2016 Phase 1
NCT02822157 Not yet recruiting Ovarian Epithelial Cancer Universitaire Ziekenhuizen Leuven|AstraZeneca August 2016 Phase 2
NCT02810743 Not yet recruiting Breast Cancer The Netherlands Cancer Institute August 2016 Phase 3
NCT02489006 Not yet recruiting Ovarian Cancer|Fallopian Tube Cancer|Neoadjuvant Treatment|Debulking Surgical Procedures University Health Network, Toronto July 2016 Phase 2
NCT02392676 Withdrawn Platinum Sensitive Relapsed Ovarian Cancer AstraZeneca|Myriad Genetic Laboratories, Inc. July 2016 Phase 3

view more

Chemical Information

Download Olaparib (AZD2281, Ku-0059436) SDF
Molecular Weight (MW) 434.46
Formula

C24H23FN4O3

CAS No. 763113-22-0
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 86 mg/mL warming (197.94 mM)
Water 0.002 mg/mL (0.0 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 4% DMSO+30% PEG 300+ddH2O 5mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 4-(3-(1-(cyclopropanecarbonyl)piperazine-4-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one

Frequently Asked Questions

  • Question 1
    How long can the chemical compound be stable in DMEM at 4 ℃?

    Answer: The compound is stable in DMEM at 4 degree for one week.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related PARP Products

  • G007-LK

    G007-LK is a potent and selective tankyrase inhibitor with IC50 of 46 nM and 25 nM for TNKS1/2, respectively.

  • NU1025

    NU1025 is a potent PARP inhibitor with IC50 of 400 nM.

  • SCR7

    SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ).

  • Veliparib (ABT-888)

    Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3.

    Features:Increases the efficacy of common cancer therapies such as radiation and alkylating agents.

  • Rucaparib (AG-014699,PF-01367338)

    Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.

    Features:The first PARP inhibitor used in clinical trials combined with temozolomide.

  • Talazoparib (BMN 673)

    Talazoparib (BMN 673) is a novel PARP inhibitor with IC50 of 0.58 nM in a cell-free assay. It is also a potent inhibitor of PARP-2, but does not inhibit PARG and is highly sensitive to PTEN mutation. Phase 3.

    Features:Most potent and selective PARPi reported thus far.

  • Iniparib (BSI-201)

    Iniparib (BSI-201) is a PARP1 inhibitor with demonstrated effectiveness in triple-negative breast cancer (TNBC). Phase 3.

  • PJ34 HCl

    PJ34 HCl is the hydrochloride salt of PJ34, which is a PARP inhibitor with EC50 of 20 nM and is equally potent to PARP1/2.

    Features:Water-soluble PARP1/2 inhibitor with >10,000-fold potentcy vs. 3-aminobenzamide (prototypical PARP inhibitor). Potential uses in cardiovascular diseases (stroke, cerebral ischemia, & myocardial ischemia).

  • AG-14361

    AG14361 is a potent inhibitor of PARP1 with Ki of <5 nM in a cell-free assay. It is at least 1000-fold more potent than the benzamides.

    Features:The 1st high-potency PARP-1 inhibitor with the specificity & in vivo activity to enhance chemotherapy and radiation therapy of human cancers.

  • A-966492

    A-966492 is a novel and potent inhibitor of PARP1 and PARP2 with Ki of 1 nM and 1.5 nM, respectively.

    Features:A promising, structurally diverse benzimidazole analogue that is being further characterized preclinically.

Recently Viewed Items

Tags: buy Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) supplier | purchase Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) cost | Olaparib (AZD2281, Ku-0059436) manufacturer | order Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us